Jubilant Pharmova
Ticker > Company >

Jubilant Pharmova share price

Jubilant Pharmova Ltd.

NSE: JUBLPHARMA BSE: 530019 SECTOR: Pharmaceuticals & Drugs  1.49 L   499   90

1109.10
+3.20 (0.29%)
BSE: Today, 02:54 PM

Price Summary

Today's High

₹ 1113.95

Today's Low

₹ 1088.35

52 Week High

₹ 1309

52 Week Low

₹ 823.7

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 17665.87 Cr.

Enterprise Value

₹ 17959.37 Cr.

No. of Shares

15.93 Cr.

P/E

527.34

P/B

7.65

Face Value

₹ 1

Div. Yield

0.45 %

Book Value (TTM)

₹  144.98

CASH

₹ 12.6 Cr.

DEBT

₹ 306.1 Cr.

Promoter Holding

47.68 %

EPS (TTM)

₹  2.1

Sales Growth

-4.97%

ROE

0.82 %

ROCE

2.52%

Profit Growth

-39.24 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 19Indices.

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
44390
  114.25 (0.258041930402086%)

NIFTY500

Nifty 500
22946.9
  68.25 (0.298313056058808%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
19743.25
  32.4000000000015 (0.16437647285632%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
17636.5
  42.4500000000007 (0.241274749133935%)

NIFTYSMALLCAP250

Nifty Smallcap 250
16978.95
  43.7999999999993 (0.258633670206643%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15990.8
  42.9499999999989 (0.269315299554473%)

NFT500EQUAL

Nifty 500 Equal Weight
14263.8
  21.2999999999993 (0.149552395997898%)

NIFTYTOTALMCAP

Nifty Total Market index
12918.15
  37.6499999999996 (0.292302317456627%)

NIFTYFULLMIDCAP100

NIFTY FULL MIDCAP 100
5987.56
  -42.7999999999993 (-0.709742038617911%)

SMLCAP

S&P Bse Small Cap
53006.94
  96.3100000000049 (0.182023914665175%)

BSE HC

S&P Bse Healthcare
44332.98
  205.910000000003 (0.466629667458096%)

BSE500MOM50

BSE 500 Momentum 50
42667.27
  221.459999999999 (0.521747611837298%)

BSE500

S&P Bse 500
36008.85
  92.6599999999962 (0.257989502784106%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
11963.68
  18.4600000000009 (0.154538802968895%)

BSE1000

Bse 1000
10733.19
  26.8999999999996 (0.251254169278048%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

SML250

S&P Bse 250 SmallCap
6793.53
  18.21 (0.268769593170504%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-4.97%
3 Year0.91%
5 Year-24.99%

Profit Growth

1 Year-39.24%
3 Year-37.98%
5 Year-43.07%

ROE%

1 Year0.82%
3 Year1.4%
5 Year3.91%

ROCE %

1 Year2.52%
3 Year2.94%
5 Year5%

Debt/Equity

0.1328

Price to Cash Flow

130.28

Interest Cover Ratio

2.2617

CFO/PAT (5 Yr. Avg.)

2.06872193031008

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 47.68 0.00
Mar 2025 50.68 0.00
Dec 2024 50.68 0.00
Sep 2024 50.68 0.00
Jun 2024 50.68 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 15.6672 days.
  • The company has a good cash flow management; CFO/PAT stands at 2.06872193031008.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.30414607945004.

 Limitations

  • The company has shown a poor profit growth of -37.9822265736043% for the Past 3 years.
  • The company has shown a poor revenue growth of 0.908755894466973% for the Past 3 years.
  • Company has a poor ROE of 1.40163333333333% over the past 3 years.
  • Company has a poor ROCE of 2.9432% over the past 3 years
  • The company is trading at a high PE of 527.34.
  • The company is trading at a high EV/EBITDA of 147.3255.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 53.2 165.7 196 217.3 59.5
Total Expenditure 43.4 171.8 185 191.3 49.2
Operating Profit 9.8 -6.1 11 26 10.3
Other Income 0.3 43.8 18.4 17.9 0.7
Interest 3.3 7.8 7.4 7 3
Depreciation 1.9 13.3 13.3 13.4 1.5
Exceptional Items 0 0 0 0 0
Profit Before Tax 4.9 16.6 8.7 23.5 6.5
Tax 0.5 6.1 3.4 9.9 2.4
Profit After Tax 4.4 10.5 5.3 13.6 4.1
Adjusted EPS (Rs) 0.28 0.66 0.33 0.86 0.26

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 2709.5 725.73 810.1 784.7 745.7
Total Expenditure 2282.44 719.27 807 768.2 713.6
Operating Profit 427.06 6.46 3.1 16.5 32.1
Other Income 47.88 126.16 137.9 103.4 99.6
Interest 101.8 10.99 18.5 29.9 29.8
Depreciation 99.97 36.91 43.2 48.3 53.1
Exceptional Items 0 0 0 0 -11.2
Profit Before Tax 273.17 84.72 79.3 41.7 37.6
Tax 58.69 4.23 29.4 10.1 18.4
Net Profit 214.48 80.49 49.9 31.6 19.2
Adjusted EPS (Rs.) 13.47 5.05 3.14 1.99 1.21

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 15.93 15.93 15.9 15.9 15.9
Total Reserves 1266.52 2423.14 2398.6 2358.6 2302.2
Borrowings 420 174 174 246.5 232.8
Other N/C liabilities 22 -5.1 41.7 43.6 36.8
Current liabilities 120.15 252.26 361.2 315.4 310.3
Total Liabilities 1844.6 2860.23 2991.4 2980 2898
Assets
Net Block 127.08 636.51 687.4 711.3 698.7
Capital WIP 0.33 35.26 47 37 19.3
Intangible WIP 0 0 0 0 0
Investments 1645.98 1645.75 1656.6 1656.9 1657
Loans & Advances 4.96 13.98 18.6 24.3 28.1
Other N/C Assets 0 2.92 3 9.9 10.7
Current Assets 66.25 525.81 578.8 540.6 484.2
Total Assets 1844.6 2860.23 2991.4 2980 2898
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 273.17 84.72 79.3 41.7 37.6
Adjustment 196.45 -48.68 -35.2 48.2 79.2
Changes in Assets & Liabilities 181.36 -3.42 -91.8 65.5 31.3
Tax Paid -42.6 -19.38 -17.4 -12.2 -12.5
Operating Cash Flow 608.38 -3.55 -65.1 143.2 135.6
Investing Cash Flow 116.89 93.1 31.1 -40.3 -2.3
Financing Cash Flow -781.65 -107.37 22.5 -77.8 -156.8
Net Cash Flow -56.37 -17.82 -11.5 25.1 -23.5

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 50.68 50.68 50.68 50.68 47.68
hari shanker bhartia 0.23 0.23 0.23 0.23 0.23
hsb trustee company pvt l... 19.00 19.00 19.00 19.00 19.00
kavita bhartia 0.01 0.01 0.01 0.01 0.01
mav management advisors l... 3.15 3.15 3.15 3.15 3.15
miller holdings pte ltd 3.28 3.28 3.28 3.28 3.28
nikita resources private ... 2.20 2.20 2.20 2.20 0.97
priyavrat bhartia 0.88 0.88 0.88 0.88 0.88
shamit bhartia 0.08 0.08 0.08 0.08 0.08
spb trustee company pvt l... 20.52 20.52 20.52 20.52 20.08
jubilant enpro private li... 1.33 1.33 1.33 1.33 -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 49.32 49.32 49.32 49.32 52.32
abakkus emerging opportun... 1.20 1.20 1.20 1.18 1.15
bandhan small cap fund - - - - 1.03
east bridge capital maste... 3.17 4.88 3.92 4.30 2.78
government pension fund g... 3.75 3.71 3.45 3.47 3.43
investor education and pr... 1.24 1.24 - 1.25 1.25
kotak funds - india midca... - - - - 1.00
kotak mahindra trustee co... - - - - 2.37
llp - 0.27 0.28 0.21 0.22
quant mutual fund - quant... 1.92 1.92 1.92 1.85 1.85
rekha jhunjhunwala 6.57 6.43 3.15 6.43 6.43
sbi life insurance co. lt... - - 1.39 1.32 1.13
theleme india master fund... 1.37 1.33 1.32 1.46 1.56
estate of late mr. rakesh... - - 3.28 - -
investor education and pr... - - 1.25 - -
non resident non repartri... - 0.74 - - -
east bridge capital maste... 4.18 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit FITCH
Credit FITCH
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit INDIA RATINGS & RESEARCH
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research Motilal Oswal
Research Nirmal Bang Institutional
Research Prabhudas Lilladhar
Research HDFC Securities

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY22
Concall Q2FY21
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY24
Presentation Q4FY21
Presentation Q4FY21
Presentation Q4FY21
Presentation Q3FY25
Presentation Q3FY24
Presentation Q2FY24
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY24
Presentation Q1FY21

Company News

Jubilant Pharmova completes transfer of API business to Jubilant Biosys 2 Sep, 11:58 AM USFDA concludes PAI at Jubilant Pharmova’s arm's facility at Roorkee 2 Aug, 4:10 PM Jubilant Pharmova informs about communication 2 Aug, 9:46 AM Jubilant Pharmova informs about newspaper publication 30 Jul, 6:00 PM Jubilant Pharmova - Quaterly Results 29 Jul, 1:35 PM Jubilant Pharmova - Quaterly Results 29 Jul, 1:35 PM Jubilant Pharmova - Quaterly Results 29 Jul, 1:35 PM Jubilant Pharmova gets nod to sell, transfer API business to Jubilant Biosys 13 Jun, 12:21 PM Jubilant Pharmova - Quaterly Results 16 May, 1:28 PM Jubilant Pharmova - Quaterly Results 16 May, 1:28 PM Jubilant Pharmova - Quaterly Results 16 May, 1:28 PM Jubilant Pharmova’s arm inks Shareholders’ Agreement with Pierre Fabre SA 20 Mar, 2:59 PM Jubilant Pharmova's arm gets EIR with VAI status for Maryland facility 13 Mar, 10:59 AM Jubilant Pharmova - Quaterly Results 31 Jan, 1:05 PM Jubilant Pharmova - Quaterly Results 31 Jan, 1:05 PM Jubilant Pharmova - Quaterly Results 31 Jan, 1:05 PM Jubilant Pharmova’s arm voluntary pays $25 million term loan 27 Jan, 10:11 AM Jubilant Pharmova informs about board meeting 23 Jan, 12:17 PM Jubilant Pharmova informs about disclosure 17 Jan, 9:54 AM USFDA completes inspection at Jubilant Pharmova’s arm’s solid oral formulations facility at Salisbury 17 Jan, 9:22 AM Jubilant Pharmova informs about board meeting 25 Oct, 4:43 PM Jubilant Pharmova informs about outcome of board meeting 25 Oct, 4:33 PM Jubilant Pharmova - Quaterly Results 25 Oct, 12:26 PM Jubilant Pharmova - Quaterly Results 25 Oct, 12:26 PM Jubilant Pharmova - Quaterly Results 25 Oct, 12:26 PM Jubilant Pharmova informs about deletion of tax demand raised on Jubilant Generics 10 Oct, 4:58 PM Jubilant Pharmova informs about disclosure 20 Sep, 12:49 PM Jubilant Pharmova’s arm gets VAI classification for USA manufacturing facility 10 Sep, 4:28 PM Jubilant Pharmova’s step down arm signs, issues put option offer to Pierre Fabre Laboratories 19 Aug, 11:15 AM Jubilant Pharmova informs about AGM notice and annual report 9 Aug, 9:12 AM Jubilant Pharmova informs about disclosure 27 Jul, 12:21 PM Jubilant Pharmova informs about disclosure 20 Jul, 11:48 AM Jubilant Pharmova reports many fold jump in Q1 consolidated net profit 19 Jul, 4:25 PM Jubilant Pharmova informs about outcome of board meeting 19 Jul, 3:36 PM Jubilant Pharmova informs about press release and earnings presentation 19 Jul, 3:34 PM Jubilant Pharmova - Quaterly Results 19 Jul, 2:08 PM Jubilant Pharmova - Quaterly Results 19 Jul, 2:08 PM Jubilant Pharmova - Quaterly Results 19 Jul, 2:08 PM Jubilant Pharmova informs about completion of voluntary prepayment 25 Jun, 2:20 PM USFDA concludes audit at contract manufacturing facility of Jubilant Pharmova’s step down arm 18 Jun, 5:43 PM USFDA concludes audit at Washington manufacturing facility of Jubilant Pharmova’s arm 10 Jun, 11:53 AM Jubilant Pharmova acquires 19.89% stake in O2 Renewable Energy XVI 7 Jun, 12:29 PM Jubilant Pharmova - Quaterly Results 29 May, 2:56 PM Jubilant Pharmova - Quaterly Results 29 May, 2:56 PM Jubilant Pharmova - Quaterly Results 29 May, 2:56 PM Jubilant Pharmova’s arm approves proposal for investment in Isharays Energy 29 May, 10:42 AM USFDA concludes audit at Radiopharmaceutical manufacturing facility of Jubilant Pharmova’s arm 25 Apr, 10:14 AM Jubilant Pharmova informs about closure of manufacturing operations 18 Apr, 10:05 AM Jubilant Pharmova informs about updates on acquisition 30 Mar, 12:18 PM Jubilant Pharmova informs about change in directorate 26 Mar, 4:52 PM

Jubilant Pharmova Stock Price Analysis and Quick Research Report. Is Jubilant Pharmova an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Jubilant Pharmova. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Jubilant Pharmova has a PE ratio of 525.294788893115 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Jubilant Pharmova has ROA of 0.6533% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Jubilant Pharmova has a Current ratio of 1.5604.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Jubilant Pharmova has a ROE of 0.8227%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Jubilant Pharmova has a Debt to Equity ratio of 0.1328 which means that the company has low proportion of debt in its capital.

  • Sales growth: Jubilant Pharmova has reported revenue growth of -4.9701% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Jubilant Pharmova for the current financial year is 4.30468016628671%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Jubilant Pharmova is Rs 5 and the yield is 0.4573%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Jubilant Pharmova is Rs 2.1032. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Jubilant Pharmova in Ticker for free. Also, one can get the intrinsic value of Jubilant Pharmova by using Valuation Calculators, which are available with a Finology ONE subscription. 

Jubilant Pharmova FAQs

Q1. What is Jubilant Pharmova share price today?
Ans: The current share price of Jubilant Pharmova is Rs 1104.8.

Q2. What is the market capitalisation of Jubilant Pharmova?
Ans: Jubilant Pharmova has a market capitalisation of Rs 17597.38023672 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Jubilant Pharmova?
Ans: The PE ratio of Jubilant Pharmova is 525.294788893115 and the P/B ratio of Jubilant Pharmova is 7.62013016572818, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Jubilant Pharmova share?
Ans: The 52-week high share price of Jubilant Pharmova is Rs 1309.9, and the 52-week low share price of Jubilant Pharmova is Rs 802.

Q5. Does Jubilant Pharmova pay dividends?
Ans: Currently, Jubilant Pharmova pays dividends. Dividend yield of Jubilant Pharmova is around 0.4573%.

Q6. What are the face value and book value of Jubilant Pharmova shares?
Ans: The face value of Jubilant Pharmova shares is Rs 1, while the book value per share of Jubilant Pharmova is around Rs 144.9844. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Jubilant Pharmova?
Ans: Jubilant Pharmova has a total debt of Rs 306.1 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Jubilant Pharmova?
Ans: The ROE of Jubilant Pharmova is 0.8227% and ROCE of Jubilant Pharmova is 2.5236%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Jubilant Pharmova a good buy for the long term?
Ans: The Jubilant Pharmova long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Jubilant Pharmova undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Jubilant Pharmova appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Jubilant Pharmova’s financials?
Ans: You can review Jubilant Pharmova’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Jubilant Pharmova

Jubilant Pharmova Ltd. Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis

Jubilant Pharmova Ltd. is a leading pharmaceutical company with a strong presence in the global market. In this stock analysis, we will delve into various aspects of the company that would be of interest to long-term stock investors.

Jubilant Pharmova Ltd. Share Price

The share price of Jubilant Pharmova Ltd. reflects the market valuation of the company's stock. It is influenced by various factors such as industry trends, market conditions, and the overall performance of the company. To gain insights into the historical and current stock price, investors can refer to the price chart available on our website. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions.

Jubilant Pharmova Ltd. Balance Sheet

The balance sheet of Jubilant Pharmova Ltd. provides a snapshot of the company's financial health at a given point in time. It presents the company's assets, liabilities, and shareholders' equity. Investors can analyze the balance sheet to assess the company's solvency, liquidity, and financial stability.

Jubilant Pharmova Ltd. Annual Report

Jubilant Pharmova Ltd. publishes an annual report that provides a comprehensive overview of the company's performance throughout the year. It covers key highlights, financial statements, management discussions, and analysis of the business operations. Investors can download the annual reports from our website to gain deeper insights into the company's strategies and prospects.

Jubilant Pharmova Ltd. Dividend

Dividends are a way for companies to distribute a portion of their profits to shareholders. Jubilant Pharmova Ltd. declares dividends periodically based on its financial performance and policies. For information on historical dividends, investors can explore our pre-built screening tools that provide relevant data to aid in their analysis.

Jubilant Pharmova Ltd. Quarterly Results

Jubilant Pharmova Ltd. releases quarterly results to keep investors updated on the company's performance on a shorter time frame. These results include financial statements, management discussions, and insights into the industry dynamics. Investors can access the quarterly results as downloadable documents on our website.

Jubilant Pharmova Ltd. Stock Price

The stock price of Jubilant Pharmova Ltd. is influenced by various factors such as market demand, industry trends, and company-specific developments. By analyzing the stock price, investors can gain insights into market sentiments towards the company's prospects.

Jubilant Pharmova Ltd. Price Chart

Our website provides a comprehensive price chart that allows investors to track the historical performance of Jubilant Pharmova Ltd.'s stock. By analyzing the price movements and trends, investors can make informed decisions regarding their investments. Our website provides pre-built screening tools to help investors analyze stock price and performance.

Jubilant Pharmova Ltd. News

Stay up to date with the latest news and developments related to Jubilant Pharmova Ltd. Our website provides a dedicated section where investors can access news articles, press releases, and industry updates concerning the company.

Jubilant Pharmova Ltd. Concall Transcripts

We understand the importance of access to concall transcripts for investors. Concalls provide valuable insights into the company's performance and future prospects. Investors can obtain and review Jubilant Pharmova Ltd.'s concall transcripts from our website.

Jubilant Pharmova Ltd. Investor Presentations

Jubilant Pharmova Ltd. conducts investor presentations to provide a deeper understanding of its business operations and growth strategies. Our website offers access to these presentations, allowing investors to stay informed about the company's developments and investment opportunities.

Jubilant Pharmova Ltd. Promoters

The promoters of Jubilant Pharmova Ltd. are key stakeholders who have a significant influence on the company's decision-making and overall direction. Investors are encouraged to learn more about the promoters and their track record to assess the company's governance and stability.

Jubilant Pharmova Ltd. Shareholders

Understanding the shareholder base of Jubilant Pharmova Ltd. provides insights into the ownership structure and potential influence on the company's decision-making. Investors can explore our pre-built screening tools to access data and information on the company's shareholders.

In addition to the comprehensive stock analysis provided, Ticker offers premium features and tools. These include DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis. These tools can assist investors in conducting a more in-depth analysis of Jubilant Pharmova Ltd.'s stock and making informed investment decisions.

By providing downloadable annual reports and quarterly results on our website, we aim to facilitate easy access to the information necessary for investors to conduct their analysis.

Jubilant Pharmova Limited ROCE

The Return on Capital Employed (ROCE) measures a company's ability to generate profits from its invested capital. As an investor, understanding this ratio is crucial in evaluating the financial performance of Jubilant Pharmova Limited. Our stock analysis page provides you with the ROCE data for the company, enabling you to make informed investment decisions. You can find this information in the financials table or ratio section above. ROCE helps you assess how efficiently Jubilant Pharmova Limited is utilizing its capital to generate returns.

Jubilant Pharmova Limited EBITDA

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a key metric that sheds light on a company's operational profitability. By considering non-operating factors, EBITDA provides a clearer picture of Jubilant Pharmova Limited's core business performance. Our stock analysis page offers you the EBITDA data for the company, allowing you to assess its operational efficiency. You can find this information conveniently in the financials table or ratio section above.

Jubilant Pharmova Limited DPS

Dividends per Share (DPS) is an essential indicator for investors seeking income from their investments. By providing the DPS data for Jubilant Pharmova Limited, our stock analysis page allows you to evaluate the company's dividend distribution over time. You can access this information in the financials table or ratio section above. DPS is an important metric as it reflects the commitment of Jubilant Pharmova Limited to sharing its profits with shareholders.

Jubilant Pharmova Limited EPS

Earnings per Share (EPS) is a crucial measure of a company's profitability. By presenting the EPS data for Jubilant Pharmova Limited, our stock analysis page enables you to gauge the company's earnings generation on a per-share basis. You can access this information in the financials table or ratio section above. EPS is widely used by investors to assess the financial performance and potential future growth of Jubilant Pharmova Limited. 

Jubilant Pharmova Reserves Analysis

From March 2020 to March 2024, Jubilant Pharmova's total reserves displayed significant fluctuations, starting at Rs 2,591.37 Cr in March 2020, dipping to Rs 1,266.52 Cr in March 2021, and making a recovery to Rs 2,423.14 Cr in March 2022. As of March 2023, reserves are slightly reduced at Rs 2,398.60 Cr and further to Rs 2,358.60 Cr in March 2024, indicating a trend of moderate stabilization.

Jubilant Pharmova Debt Insight

The borrowing trend shows a sharp decrease from Rs 1,327.91 Cr in March 2020 to Rs 420 Cr in March 2021 and then substantially dropping to Rs 174 Cr by March 2022. The amount remained steady at Rs 174 Cr in March 2023 before seeing a slight increase to Rs 246.50 Cr in March 2024.

Jubilant Pharmova Assets Overview

Jubilant Pharmova's total assets align closely with its liabilities, maintaining a balanced sheet from Rs 5,433.39 Cr in March 2020, dipping to its lowest at Rs 1,844.60 Cr in March 2021, before gradually increasing to Rs 2,980 Cr by March 2024. Notably, the investments remain relatively stable at around Rs 1,656.90 Cr by March 2024.

This data is an analysis for the Standalone Balance Sheet of the company. In navigating the broader financial landscape, investors frequently regard such detailed balance sheet analytics as a cornerstone in screening potential investment opportunities across various sectors or considering IPOs on indexes like NSE/BSE.

Read More
X